nifedipine has been researched along with Edema, Pulmonary in 64 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-concentration NO inhalation on the basis of conventional and nifedipine therapies was very effective in the treatment of high-altitude pulmonary edema, which deserves further and larger scale investigation." | 9.08 | [Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema]. ( Ma, Y; Wang, W; Zhang, X, 1998) |
| "Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude." | 9.07 | Prevention of high-altitude pulmonary edema by nifedipine. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P, 1991) |
| "To evaluate the risk of developing pulmonary edema in women exposed to nifedipine, magnesium sulfate (MgSO4), or both in a preterm setting." | 7.80 | Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. ( Abenhaim, HA; Gangal, M; Xiao, C, 2014) |
| " We report the first case of acute pulmonary edema following tocolytic oral nifedipine." | 7.73 | Acute pulmonary edema during tocolytic therapy with nifedipine. ( Abbas, OM; Kanj, NA; Nassar, AH; Usta, IM, 2006) |
| "A 34-year-old man with primary pulmonary hypertension developed acute nonhemodynamic pulmonary edema after a loading dose of nifedipine." | 7.68 | Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. ( Decroly, P; Gottignies, P; Prigogine, T; Verhoeven, A; Waterlot, Y, 1991) |
| "Nifedipine, a potent coronary vasodilator, was administered in a single sublingual dose of 20 mg to eight patients with mild to moderate congestive heart failure." | 7.66 | Hemodynamic effects of nifedipine in congestive heart failure. ( Ito, T; Ito, Y; Matsumoto, S; Okabe, F; Sada, T; Sato, M; Sekine, I; Su, KM; Takahashi, M; Ueda, A, 1980) |
| "Low-concentration NO inhalation on the basis of conventional and nifedipine therapies was very effective in the treatment of high-altitude pulmonary edema, which deserves further and larger scale investigation." | 5.08 | [Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema]. ( Ma, Y; Wang, W; Zhang, X, 1998) |
| "Nifedipine has been shown effective for prevention and treatment of high altitude pulmonary edema (HAPE)." | 5.07 | Nifedipine does not prevent acute mountain sickness. ( Bärtsch, P; Goerre, S; Hohenhaus, E; Niroomand, F; Oelz, O; Vock, P, 1994) |
| "Twenty-one mountaineers (1 woman and 20 men) with a history of radiographically documented high-altitude pulmonary edema were randomly assigned to receive either 20 mg of a slow-release preparation of nifedipine (n = 10) or placebo (n = 11) every 8 hours while ascending rapidly (within 22 hours) from a low altitude to 4559 m and during the following three days at this altitude." | 5.07 | Prevention of high-altitude pulmonary edema by nifedipine. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P, 1991) |
| "To evaluate the risk of developing pulmonary edema in women exposed to nifedipine, magnesium sulfate (MgSO4), or both in a preterm setting." | 3.80 | Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. ( Abenhaim, HA; Gangal, M; Xiao, C, 2014) |
| "Labetalol is commonly used for control of hypertension in pregnancy." | 3.77 | False-positive amphetamine toxicology screen results in three pregnant women using labetalol. ( Wu, D; Yee, LM, 2011) |
| "We report the case of a 31-yr-old parturient at 34 weeks gestation of a twin pregnancy, who experienced acute pulmonary edema after tocolytic treatment with nifedipine, nicardipine and atosiban of > 48 hr in duration." | 3.74 | [Non-invasive ventilation for pulmonary edema associated with tocolytic agents during labour for a twin pregnancy]. ( Bazin, JE; Bolandard, F; Chanséaume, S; Constantin, JM; Gallot, D; Perbet, S; Vignaud, M; Zénut, M, 2008) |
| " We report the first case of acute pulmonary edema following tocolytic oral nifedipine." | 3.73 | Acute pulmonary edema during tocolytic therapy with nifedipine. ( Abbas, OM; Kanj, NA; Nassar, AH; Usta, IM, 2006) |
| "A 37-year-old woman presented with persistent hypotension and noncardiogenic pulmonary edema after massive nifedipine overdose." | 3.71 | Continuous calcium chloride infusion for massive nifedipine overdose. ( Lam, YM; Lau, CP; Tse, HF, 2001) |
| " Nitroglycerin was named as first choice only for pulmonary oedema or myocardial infarction." | 3.70 | [Diagnostic and therapeutic procedures by doctors for patients in a hypertensive crisis. An inquiry in 56 internal medicine clinics]. ( Grieshaber, M; Schwietzer, G; Stahl, RA; Wenzel, UO, 1998) |
| "The combination of nifedipine and prazosin was more successful in preventing myocardial damage in 16 patients with hypertension than was nifedipine alone in two other patients with hypertension." | 3.68 | Management of the cardiovascular manifestations of poisoning by the Indian red scorpion (Mesobuthus tamulus). ( Bawaskar, HS; Bawaskar, PH, 1992) |
| "A 34-year-old man with primary pulmonary hypertension developed acute nonhemodynamic pulmonary edema after a loading dose of nifedipine." | 3.68 | Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension. ( Decroly, P; Gottignies, P; Prigogine, T; Verhoeven, A; Waterlot, Y, 1991) |
| " In a canine model of asymmetric oleic acid-induced pulmonary edema, we examined this possibility by studying the effect of 20 and 40-micrograms/kg doses of parenteral nifedipine on oxygenation variables, venous admixture, and intrapulmonary blood flow distribution." | 3.68 | Effect of nifedipine on oxygen delivery in canine asymmetric oleic acid lung injury. ( Johnston, WE; Tommasi, E; Vinten-Johansen, J, 1990) |
| "Nifedipine, a potent coronary vasodilator, was administered in a single sublingual dose of 20 mg to eight patients with mild to moderate congestive heart failure." | 3.66 | Hemodynamic effects of nifedipine in congestive heart failure. ( Ito, T; Ito, Y; Matsumoto, S; Okabe, F; Sada, T; Sato, M; Sekine, I; Su, KM; Takahashi, M; Ueda, A, 1980) |
| "High altitude pulmonary edema (HAPE) is characterized by marked pulmonary hypertension." | 2.67 | Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. ( Bärtsch, P; Maggiorini, M; Noti, C; Oelz, O; Ritter, M; Vock, P; Waber, U, 1992) |
| "High-altitude pulmonary edema and high-altitude cerebral edema are potentially fatal conditions." | 2.44 | High-altitude illness and muscle physiology. ( Bosco, JA; Glassner, PJ; Weil, WM, 2007) |
| "High-altitude pulmonary edema is a non-cardiac edema that often precedes acute mountain sickness." | 2.42 | [Visiting high altitudes--healthy persons and patients with risk diseases]. ( Fischer, R, 2004) |
| "Symptoms and signs of high altitude cerebral edema are severe headache, which is not relieved by acetaminophen, loss of movement coordination, ataxia and mental deterioration ending in coma." | 2.41 | [Mountaineering and altitude sickness]. ( Maggiorini, M, 2001) |
| "High-altitude pulmonary edema (HAPE) occurs in unacclimatized individuals who are rapidly exposed to altitudes in excess of 2450 m." | 2.39 | High-altitude pulmonary edema: current concepts. ( Hultgren, HN, 1996) |
| "High-altitude pulmonary edema (HAPE), a severe form of acute mountain sickness, is a potentially fatal complication of acute exposure to high altitude." | 2.38 | What's up in the management of high-altitude pulmonary edema? ( Tso, EL; Wagner, TJ, 1993) |
| "Individuals susceptible to high altitude pulmonary edema also show increased hypoxia vasoconstriction of pulmonary arterioles." | 2.38 | [Who gets altitude sickness?]. ( Bärtsch, P, 1992) |
| "High altitude pulmonary edema (HAPE) is a life-threatening altitude illness that usually occurs in insufficiently acclimatized climbers in the first few days at altitudes above 2500 m." | 1.51 | Delayed-Onset High Altitude Pulmonary Edema: A Case Report. ( Acharya, S; Bhattarai, A; Wilkes, M; Yadav, JK, 2019) |
| "Nifedipine may cause cardiorespiratory adverse effects warranting a close monitoring." | 1.42 | [Adverse effects and hemodynamic effects of nifedipine as a tocolytic]. ( Audibert, F; Bussières, JF; Carceller, AM; Ferreira, E; Lachance, C; Martin, B; Spiesser-Robelet, L; Touzin, K, 2015) |
| "High altitude pulmonary edema (HAPE) is the leading cause of death from altitude illness and rapid descent is often considered a life-saving foundation of therapy." | 1.34 | Treatment of high altitude pulmonary edema at 4240 m in Nepal. ( Fagenholz, PJ; Gutman, JA; Harris, NS; Murray, AF, 2007) |
| "High-altitude pulmonary edema (HAPE) is a non-cardiogenic edema that is often preceded by symptoms of AMS." | 1.32 | [Acute mountain sickness and high-altitude pulmonary edema. How to protect the mountain climber from the effects of the "altitude haze"]. ( Bärtsch, P; Dehnert, Ch; Mairbäurl, H; Schneider, M, 2003) |
| "Among 21 patients, 26 pulmonary edema attacked, 9 of them had upper have respiratory diseases, thirteen cases caused by improper infusion." | 1.31 | [Analysis of inductive factors, diagnosis and treatment of 21 cases with pregnancy accompanied with pulmonary edema]. ( Wang, S; Zhang, L; Zhao, Y, 2001) |
| "High altitude pulmonary edema is characterized hemodynamically by a markedly restricted pulmonary vascular bed." | 1.28 | The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison. ( Greene, ER; Hackett, PH; Hartig, GS; Levine, BD; Roach, RC, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (17.19) | 18.7374 |
| 1990's | 28 (43.75) | 18.2507 |
| 2000's | 19 (29.69) | 29.6817 |
| 2010's | 6 (9.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattarai, A | 1 |
| Acharya, S | 1 |
| Yadav, JK | 1 |
| Wilkes, M | 1 |
| Kutuk, MS | 1 |
| Ozgun, MT | 1 |
| Uludag, S | 1 |
| Dolanbay, M | 1 |
| Yildirim, A | 1 |
| Xiao, C | 1 |
| Gangal, M | 1 |
| Abenhaim, HA | 1 |
| Spiesser-Robelet, L | 1 |
| Martin, B | 1 |
| Carceller, AM | 1 |
| Bussières, JF | 1 |
| Touzin, K | 1 |
| Audibert, F | 1 |
| Lachance, C | 1 |
| Ferreira, E | 1 |
| Chandramoorthi, GD | 1 |
| Piramanayagam, S | 1 |
| Marimuthu, P | 1 |
| Perbet, S | 1 |
| Constantin, JM | 1 |
| Bolandard, F | 1 |
| Vignaud, M | 1 |
| Gallot, D | 1 |
| Chanséaume, S | 1 |
| Zénut, M | 1 |
| Bazin, JE | 1 |
| Berendsen, RR | 1 |
| Willems, JH | 1 |
| Bosch, FH | 2 |
| Hulsebosch, R | 1 |
| Kayser, B | 2 |
| Luks, AM | 1 |
| McIntosh, SE | 1 |
| Grissom, CK | 1 |
| Auerbach, PS | 1 |
| Rodway, GW | 1 |
| Schoene, RB | 2 |
| Zafren, K | 1 |
| Hackett, PH | 3 |
| Yee, LM | 1 |
| Wu, D | 1 |
| Dehnert, Ch | 1 |
| Schneider, M | 1 |
| Mairbäurl, H | 1 |
| Bärtsch, P | 10 |
| Fischer, R | 1 |
| Carbonne, B | 2 |
| Papatsonis, DN | 1 |
| Flenady, VJ | 1 |
| Dekker, GA | 1 |
| King, JF | 1 |
| Abbas, OM | 1 |
| Nassar, AH | 2 |
| Kanj, NA | 1 |
| Usta, IM | 2 |
| Maggiorini, M | 6 |
| Ghazeeri, G | 1 |
| Weil, WM | 1 |
| Glassner, PJ | 1 |
| Bosco, JA | 1 |
| Fagenholz, PJ | 1 |
| Gutman, JA | 1 |
| Murray, AF | 1 |
| Harris, NS | 1 |
| Gatault, P | 1 |
| Genee, O | 1 |
| Legras, A | 1 |
| Garot, D | 1 |
| Mercier, E | 1 |
| Fichet, J | 1 |
| Ram, CV | 2 |
| Matsumoto, S | 1 |
| Ito, T | 1 |
| Sada, T | 1 |
| Takahashi, M | 1 |
| Su, KM | 1 |
| Ueda, A | 1 |
| Okabe, F | 1 |
| Sato, M | 1 |
| Sekine, I | 1 |
| Ito, Y | 1 |
| Gillmer, DJ | 1 |
| Kark, P | 1 |
| Bawaskar, HS | 3 |
| Bawaskar, PH | 3 |
| Hohenhaus, E | 1 |
| Niroomand, F | 1 |
| Goerre, S | 1 |
| Vock, P | 5 |
| Oelz, O | 10 |
| Mehd, US | 1 |
| Nanavati, PR | 1 |
| Ravichandran, P | 1 |
| Tso, EL | 1 |
| Wagner, TJ | 1 |
| Chaouat, A | 1 |
| Kessler, R | 1 |
| Weitzenblum, E | 1 |
| Hultgren, HN | 1 |
| Aslam, M | 1 |
| Khan, MZ | 1 |
| Wenzel, UO | 1 |
| Stahl, RA | 1 |
| Grieshaber, M | 1 |
| Schwietzer, G | 1 |
| Epstein, M | 1 |
| Lam, YM | 1 |
| Tse, HF | 1 |
| Lau, CP | 1 |
| Wang, W | 1 |
| Zhang, X | 1 |
| Ma, Y | 1 |
| Roach, RC | 2 |
| Zhang, L | 1 |
| Zhao, Y | 1 |
| Wang, S | 1 |
| Polese, A | 1 |
| Fiorentini, C | 1 |
| Olivari, MT | 1 |
| Guazzi, MD | 2 |
| Jamieson, A | 1 |
| Kerr, GW | 1 |
| Ritter, M | 5 |
| Noti, C | 4 |
| Waber, U | 4 |
| Hartig, GS | 1 |
| Greene, ER | 1 |
| Levine, BD | 1 |
| Karck, M | 1 |
| Haverich, A | 1 |
| Jenni, R | 2 |
| Reinhart, WH | 1 |
| Singh, A | 1 |
| Prigogine, T | 1 |
| Waterlot, Y | 1 |
| Gottignies, P | 1 |
| Verhoeven, A | 1 |
| Decroly, P | 1 |
| Reeves, JT | 1 |
| Johnston, WE | 1 |
| Vinten-Johansen, J | 1 |
| Tommasi, E | 1 |
| Bartorelli, A | 1 |
| Pepi, M | 1 |
| Guazzi, M | 1 |
| Hasebe, N | 1 |
| Fujikane, T | 1 |
| Watanabe, M | 1 |
| Matsuhashi, H | 1 |
| Kawamura, Y | 1 |
| Yamashita, H | 1 |
| Tobise, K | 1 |
| Onodera, S | 1 |
| Baughman, KL | 1 |
| Meese, RB | 1 |
| Batra, AK | 1 |
| Segall, PH | 1 |
| Ahmed, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial[NCT02972411] | 30 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | |||
| Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.[NCT01645826] | 0 participants (Actual) | Interventional | 2012-07-31 | Withdrawn (stopped due to no participants agreed to enroll since study start) | |||
| Multicentric Evaluation of the Impact on Hypoxia Sensitivity of Patients With COVID-19[NCT05167357] | 90 participants (Anticipated) | Interventional | 2021-03-18 | Recruiting | |||
| Sickness Evaluation at Altitude With Acetazolamide at Relative Doses[NCT03828474] | Phase 1 | 108 participants (Actual) | Interventional | 2019-08-09 | Completed | ||
| Treatment of High-altitude Sleep Disturbance: A Double-blind Comparison of Temazepam Versus Acetazolamide.[NCT01519544] | 34 participants (Actual) | Interventional | 2012-03-31 | Completed | |||
| Acute Mountain Sickness Treatment: A Double-blind Comparison of Metoclopramide vs. Ibuprofen[NCT01522326] | 300 participants (Anticipated) | Interventional | 2012-03-01 | Completed | |||
| Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.[NCT01536288] | Phase 2 | 125 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure[NCT02024386] | Phase 4 | 28 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Arterial blood samples will be obtained before, during, and after the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Samples will be obtained during the fifth minute of rest prior to exercise, during the third minute of each exercise level (referred to as stage below) and during the fifth minute post exercise. Cardiac output (CO) will be calculated using the Fick Principle: CO = V̇O2/(CaO2 - Cv̄O2) where CaO2 and Cv̄O2 represent the arterial and mixed venous oxygen content, respectively. CaO2 and CvO2 will be determined from analysis of the arterial blood samples using an IL GEM 4000 analyzer. VO2 will be reported as the final 30 secon average value of each stage. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 7.53400 | 7.07000 | 15.7480 | 15.2225 | 17.3880 | 19.6775 | 19.7900 | 19.7800 | 20.3775 | 22.2100 | 22.2475 | 24.1967 | 20.8800 | 22.5067 | 20.4400 | 13.9240 | 10.9875 |
| Riociguat 0.5 mg | 8.11903 | 8.07571 | 16.1241 | 15.5680 | 18.0884 | 20.6211 | 20.9084 | 19.5537 | 22.0844 | 21.5792 | 25.2647 | 26.4806 | 25.9674 | 25.3863 | 25.4212 | 10.9825 | 8.7147 |
Arterial blood samples will be obtained before, during, and after the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Samples will be obtained during the fifth minute of rest prior to exercise, during the third minute of each exercise level (referred to as stage below) and during the fifth minute post exercise. Cardiac output (CO) will be calculated using the Fick Principle: CO = V̇O2/(CaO2 - Cv̄O2) where CaO2 and Cv̄O2 represent the arterial and mixed venous oxygen content, respectively. CaO2 and CvO2 will be determined from analysis of the arterial blood samples using an IL GEM 4000 analyzer. VO2 will be reported as the final 30 secon average value of each stage. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 6.60219 | 8.98119 | 14.6762 | 14.7501 | 16.8736 | 16.8648 | 18.4603 | 18.0927 | 20.6738 | 20.8798 | 22.5701 | 21.9477 | 22.8612 | 23.0227 | 22.0850 | 22.5198 | 11.9949 | 10.9727 |
Subject arterial oxygen saturation (SaO2) will be periodically monitored at fixed intervals via arterial blood gas measurements during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | % oxygen saturation (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 85.4400 | 83.9000 | 74.2600 | 70.9800 | 70.9200 | 69.9800 | 67.1750 | 67.7500 | 68.9500 | 68.3500 | 68.825 | 68.825 | 66.5000 | 64.8667 | 67.7000 | 82.0400 | 83.5400 |
| Riociguat 0.5 mg | 78.3333 | 81.9667 | 71.2800 | 72.5800 | 71.0800 | 73.4500 | 71.5250 | 72.2500 | 71.3400 | 70.9000 | 71.3250 | 70.1000 | 71.5000 | 67.3000 | 73.9667 | 76.3500 | 80.5833 |
Subject arterial oxygen saturation (SaO2) will be periodically monitored at fixed intervals via arterial blood gas measurements during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | % oxygen saturation (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 84.9364 | 84.4000 | 73.1545 | 74.0000 | 72.4800 | 74.2556 | 71.9333 | 73.5000 | 72.1250 | 72.0167 | 69.6333 | 72.5200 | 71.4750 | 71.9750 | 70.8500 | 68.7000 | 79.2182 | 81.2700 |
Subject pulmonary artery pressures will be continuously monitored during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 16.3800 | 17.4000 | 25.3600 | 25.0800 | 26.6600 | 27.4400 | 25.7000 | 26.8500 | 26.9750 | 27.4000 | 27.5000 | 28.1500 | 28.7667 | 29.4333 | 26.6000 | 19.3000 | 19.2800 |
| Riociguat 0.5 mg | 16.8667 | 16.6833 | 25.0000 | 26.1167 | 27.2800 | 27.0600 | 28.0200 | 28.0500 | 29.7400 | 29.3750 | 30.8400 | 28.5000 | 32.6500 | 36.1000 | 32.9333 | 18.9500 | 19.2167 |
Subject pulmonary artery pressures will be continuously monitored during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 15.6545 | 15.4900 | 26.9455 | 25.1545 | 26.5800 | 25.5100 | 26.4111 | 24.1375 | 27.2750 | 25.2167 | 28.0333 | 24.2000 | 25.9250 | 22.7000 | 20.4000 | 22.5000 | 19.1273 | 16.6700 |
Subject systemic arterial pressures will be continuously monitored via radial artery catheterization during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 96.5600 | 96.7600 | 100.1600 | 102.500 | 107.020 | 105.580 | 109.425 | 111.825 | 112.675 | 112.475 | 114.775 | 114.175 | 108.100 | 107.367 | 101.9 | 90.4800 | 95.3600 |
| Riociguat 0.5 mg | 87.8333 | 91.6000 | 93.5167 | 97.1167 | 105.480 | 107.260 | 107.580 | 114.65 | 113.140 | 117.025 | 116.500 | 124.800 | 115.900 | 143.1 | 122.700 | 89.500 | 92.0833 |
Subject systemic arterial pressures will be continuously monitored via radial artery catheterization during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | mm Hg (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 93.3182 | 91.8000 | 101.545 | 97.627 | 107.270 | 104.867 | 110.122 | 106.425 | 114.650 | 109.517 | 115.267 | 108.240 | 112.025 | 108.825 | 107.900 | 102.400 | 90.3545 | 81.7800 |
Subject ventilation rates will be monitored continuously using a multi-channel A/D converter (PowerLab™) connected to a personal computer, using Chart™ software (ADInstruments, Colorado Springs, CO) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 18.2266 | 16.4128 | 46.0238 | 42.0435 | 63.2124 | 60.8040 | 70.9060 | 69.1603 | 89.3008 | 92.8173 | 113.354 | 118.521 | 137.837 | 134.869 | 126.447 | 41.7934 | 40.7953 |
| Riociguat 0.5 mg | 14.7634 | 17.5454 | 38.3134 | 40.3488 | 52.1473 | 59.9588 | 67.3315 | 73.6560 | 89.7233 | 97.2645 | 108.857 | 121.556 | 143.373 | 145.65 | 156.669 | 32.3927 | 29.6728 |
Subject ventilation rates will be monitored continuously using a multi-channel A/D converter (PowerLab™) connected to a personal computer, using Chart™ software (ADInstruments, Colorado Springs, CO) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | L/min (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 16.8981 | 18.9289 | 40.8095 | 41.3605 | 64.6476 | 61.4905 | 81.5548 | 78.0649 | 102.499 | 96.850 | 132.789 | 126.372 | 153.233 | 151.843 | 173.819 | 156.978 | 38.1639 | 34.7268 |
Subject work rates at exhaustion (in watts) will be continuously monitored using an ergometer (exercise bicycle) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | watts (Mean) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Control Arm | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 0 | 0 |
| Riociguat 0.5 mg | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 0 | 0 |
Subject work rates at exhaustion (in watts) will be continuously monitored using an ergometer (exercise bicycle) during the VO2max exercise test in the hypobaric chamber at a simulated altitude of 15,000 feet. Exercise level will be increased every 3 minutes until test termination criteria are achieved. Measurements will be obtained at rest, every 3 minutes during the exercise test (referred to as a stage below) and at 5 minutes post exercise. Results will be reported as a 30 second average. Subjects in the Riociguat cohorts will be tested prior to receiving drug and 90 minutes after receiving drug (midway through a three hour rest period between altitude exposures). (NCT02024386)
Timeframe: At rest, every 3 minutes during the exercise test and 5 minutes after each exercise test
| Intervention | watts (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Drug: Rest | After Drug: Rest | No Drug: Stage 1 | After Drug: Stage 1 | No Drug: Stage 2 | After Drug: Stage 2 | No Drug: Stage 3 | After Drug: Stage 3 | No Drug: Stage 4 | After Drug: Stage 4 | No Drug: Stage 5 | After Drug: Stage 5 | No Drug: Stage 6 | After Drug: Stage 6 | No Drug: Stage 7 | After Drug: Stage 7 | No Drug: Post Exercise | After Drug: Post Exercise | |
| Riociguat 1.0 mg | 0 | 0 | 50 | 50 | 75 | 75 | 100 | 100 | 125 | 125 | 150 | 150 | 175 | 175 | 200 | 200 | 0 | 0 |
15 reviews available for nifedipine and Edema, Pulmonary
| Article | Year |
|---|---|
[Visiting high altitudes--healthy persons and patients with risk diseases].
Topics: Acclimatization; Acetazolamide; Acute Disease; Altitude; Altitude Sickness; Anti-Inflammatory Agents | 2004 |
High altitude-induced pulmonary oedema.
Topics: Acclimatization; Altitude Sickness; Disease Susceptibility; Humans; Hypertension, Pulmonary; Nifedip | 2006 |
High-altitude illness and muscle physiology.
Topics: Altitude; Anti-Inflammatory Agents; Brain Edema; Calcium Channel Blockers; Dexamethasone; Humans; Ni | 2007 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
What's up in the management of high-altitude pulmonary edema?
Topics: Altitude; Humans; Nifedipine; Pulmonary Edema | 1993 |
High-altitude pulmonary edema: current concepts.
Topics: Acclimatization; Altitude Sickness; Animals; Calcium Channel Blockers; Capillary Permeability; Disea | 1996 |
The role of drugs in high altitude disorders.
Topics: Acetazolamide; Altitude Sickness; Calcium Channel Blockers; Dexamethasone; Glucocorticoids; Humans; | 1996 |
Diagnosis and management of hypertensive emergencies.
Topics: Adrenergic alpha-Agonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aortic | 1999 |
[Mountaineering and altitude sickness].
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Brain Edema; Diuretics; Glucocorticoids; Humans; Mo | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
High-altitude illness.
Topics: Acetazolamide; Altitude Sickness; Brain Edema; Calcium Channel Blockers; Diagnosis, Differential; Di | 2001 |
[Pathophysiology, prevention and therapy of altitude pulmonary edema].
Topics: Aldosterone; Altitude Sickness; Cell Membrane Permeability; Epinephrine; Humans; Hypertension, Pulmo | 1992 |
[Who gets altitude sickness?].
Topics: Altitude Sickness; Blood Pressure; Disease Susceptibility; Humans; Hypoxia; Mountaineering; Nifedipi | 1992 |
Calcium channel blockade in heart failure.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Heart; Heart Failure; Hemodyna | 1989 |
Calcium channel blocking agents in congestive heart failure.
Topics: Administration, Oral; Biological Transport; Calcium; Calcium Channel Blockers; Cardiac Output; Cardi | 1986 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
6 trials available for nifedipine and Edema, Pulmonary
| Article | Year |
|---|---|
Vasodilators: scorpion envenoming and the heart (an Indian experience).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Bradycardia; Cardiovascular Diseases; Child; Ch | 1994 |
Nifedipine does not prevent acute mountain sickness.
Topics: Acute Disease; Adult; Altitude; Altitude Sickness; Disease Susceptibility; Double-Blind Method; Fema | 1994 |
[Low-concentration nitrous oxide inhalation in the treatment of high-altitude pulmonary edema].
Topics: Administration, Inhalation; Adult; Altitude Sickness; Aminophylline; Dexamethasone; Drug Therapy, Co | 1998 |
Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker.
Topics: Acute Disease; Administration, Sublingual; Adult; Altitude Sickness; Double-Blind Method; Humans; Hy | 1992 |
Prevention of high-altitude pulmonary edema by nifedipine.
Topics: Adult; Altitude Sickness; Blood Pressure; Delayed-Action Preparations; Female; Humans; Male; Middle | 1991 |
Calcium channel blockade in heart failure.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Heart; Heart Failure; Hemodyna | 1989 |
44 other studies available for nifedipine and Edema, Pulmonary
| Article | Year |
|---|---|
Delayed-Onset High Altitude Pulmonary Edema: A Case Report.
Topics: Adult; Altitude Sickness; Humans; Male; Nifedipine; Oxygen; Pulmonary Edema | 2019 |
Acute pulmonary failure due to pulmonary edema during tocolytic therapy with nifedipine.
Topics: Acute Disease; Adult; Female; Fetal Membranes, Premature Rupture; Humans; Nifedipine; Obstetric Labo | 2013 |
Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births.
Topics: Adult; Azithromycin; Case-Control Studies; Drug Synergism; Erythromycin; Female; Humans; Infant, New | 2014 |
[Adverse effects and hemodynamic effects of nifedipine as a tocolytic].
Topics: Blood Pressure; Drug-Related Side Effects and Adverse Reactions; Female; Heart Rate; Heart Rate, Fet | 2015 |
An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Altitude Sickness; Amino Acid Sequence; Binding Site | 2008 |
[Non-invasive ventilation for pulmonary edema associated with tocolytic agents during labour for a twin pregnancy].
Topics: Adult; Apgar Score; Delivery, Obstetric; Female; Humans; Infant, Newborn; Nicardipine; Nifedipine; P | 2008 |
[Serious and sometimes fatal consequences of high-altitude pulmonary oedema].
Topics: Acetazolamide; Acute Disease; Adult; Altitude Sickness; Fatal Outcome; Female; Glucocorticoids; Huma | 2008 |
Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness.
Topics: Acetazolamide; Acute Disease; Albuterol; Altitude Sickness; Brain Edema; Carbolines; Dexamethasone; | 2010 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Adult; Amphetamine; Antihypertensive Agents; Cesarean Section; Chronic Disease; Cocaine; Cross React | 2011 |
[Acute mountain sickness and high-altitude pulmonary edema. How to protect the mountain climber from the effects of the "altitude haze"].
Topics: Acetazolamide; Acute Disease; Altitude Sickness; Anti-Inflammatory Agents; Carbonic Anhydrase Inhibi | 2003 |
Comment on the article "Acute pulmonary oedema during nicardipine therapy for premature labour. Report of five cases" by Vaast P., et al. [Eur J Obstet Gynecol Reprod Biol 2004;113:98-9].
Topics: Calcium Channel Blockers; Female; Humans; Nicardipine; Nifedipine; Obstetric Labor, Premature; Pregn | 2005 |
[Your patient wants to go to the mountains. You protect him from mountain sickness and altitude edema].
Topics: Acetazolamide; Altitude Sickness; Anticonvulsants; Brain Edema; Carbolines; Carbonic Anhydrase Inhib | 2005 |
[Tocolysis with nifedipine: its use in current practice. Gynecol Obstet Fertil 2005;33:483-7].
Topics: Female; Humans; Nicardipine; Nifedipine; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; P | 2006 |
Acute pulmonary edema during tocolytic therapy with nifedipine.
Topics: Acute Disease; Adult; Calcium Channel Blockers; Female; Humans; Nifedipine; Pregnancy; Pulmonary Ede | 2006 |
Nifedipine-associated pulmonary complications in pregnancy.
Topics: Adrenal Cortex Hormones; Female; Fetal Membranes, Premature Rupture; Fluid Therapy; Humans; Nifedipi | 2007 |
Treatment of high altitude pulmonary edema at 4240 m in Nepal.
Topics: Acetazolamide; Adult; Albuterol; Altitude; Altitude Sickness; Bed Rest; Emergency Treatment; Female; | 2007 |
Calcium-channel blockers: an increasing cause of pulmonary edema during tocolytic therapy.
Topics: Administration, Sublingual; Adult; Calcium Channel Blockers; Female; Humans; Nifedipine; Obstetric L | 2008 |
Hemodynamic effects of nifedipine in congestive heart failure.
Topics: Adult; Cardiac Output; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Male; M | 1980 |
Pulmonary oedema precipitated by nifedipine.
Topics: Acute Disease; Aged; Humans; Male; Nifedipine; Pulmonary Edema; Pyridines | 1980 |
Nifedipine overdose in a 70 year old man.
Topics: Aged; Bradycardia; Drug Overdose; Humans; Hypertension; Hypotension; Male; Nifedipine; Pulmonary Ede | 1993 |
[Acute mountain sickness and high altitude pulmonary edema].
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Nifedipine; Pulmonary Edema | 1993 |
[Altitude illness].
Topics: Acetazolamide; Adult; Altitude Sickness; Diuretics; Female; Humans; Male; Nifedipine; Pulmonary Edem | 1995 |
Pulmonary oedema and pleural effusion in two patients with primary pulmonary hypertension treated with calcium channel blockers.
Topics: Calcium Channel Blockers; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Nifedipi | 1996 |
Severe envenoming by the Indian red scorpion Mesobuthus tamulus: the use of prazosin therapy.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Animals; Cardiac Output, Low; Child; Child, P | 1996 |
[Diagnostic and therapeutic procedures by doctors for patients in a hypertensive crisis. An inquiry in 56 internal medicine clinics].
Topics: Acute Disease; Administration, Sublingual; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists | 1998 |
Death from high-altitude pulmonary edema preventable by appropriate treatment.
Topics: Altitude Sickness; Delayed-Action Preparations; Emergency Treatment; Humans; Nifedipine; Pulmonary E | 2000 |
Continuous calcium chloride infusion for massive nifedipine overdose.
Topics: Adult; Calcium; Calcium Channel Blockers; Calcium Chloride; Drug Overdose; Female; Humans; Hypotensi | 2001 |
[Analysis of inductive factors, diagnosis and treatment of 21 cases with pregnancy accompanied with pulmonary edema].
Topics: Adult; Female; Humans; Nifedipine; Pregnancy; Pregnancy Complications; Pulmonary Edema; Risk Factors | 2001 |
Clinical use of a calcium antagonistic agent (nifedipine) in acute pulmonary edema.
Topics: Adult; Aged; Blood Pressure; Calcium; Cardiomyopathies; Female; Humans; Hypertension; Male; Middle A | 1979 |
Treatment of high-altitude pulmonary oedema.
Topics: Adult; Altitude Sickness; Female; Humans; Nifedipine; Pulmonary Edema | 1992 |
Management of the cardiovascular manifestations of poisoning by the Indian red scorpion (Mesobuthus tamulus).
Topics: Adult; Aged; Animals; Cardiovascular Diseases; Child; Child, Preschool; Drug Therapy, Combination; F | 1992 |
The effect of vasodilators on pulmonary hemodynamics in high altitude pulmonary edema: a comparison.
Topics: Altitude Sickness; Echocardiography, Doppler; Hemodynamics; Humans; Hydralazine; Nifedipine; Phentol | 1992 |
High altitude sickness.
Topics: Acetazolamide; Altitude Sickness; Dexamethasone; Humans; Nifedipine; Oxygen Inhalation Therapy; Pulm | 1992 |
Nifedipine and diltiazem reduce pulmonary edema formation during postischemic reperfusion of the rabbit lung.
Topics: Animals; Diltiazem; Hemodynamics; Lung Transplantation; Nifedipine; Pulmonary Edema; Rabbits; Reperf | 1992 |
[Fibrin formation: not a cause but consequence of altitude pulmonary edema].
Topics: Acute Disease; Altitude Sickness; Fibrinopeptide A; Humans; Mountaineering; Nifedipine; Pulmonary Ed | 1992 |
Nifedipine for high altitude pulmonary oedema.
Topics: Altitude Sickness; Humans; Nifedipine; Pulmonary Edema | 1991 |
Blood rheology in acute mountain sickness and high-altitude pulmonary edema.
Topics: Acute Disease; Adult; Altitude Sickness; Blood Flow Velocity; Blood Viscosity; Erythrocyte Aggregati | 1991 |
Acute nonhemodynamic pulmonary edema with nifedipine in primary pulmonary hypertension.
Topics: Acute Disease; Adult; Blood Pressure; Humans; Hypertension, Pulmonary; Male; Nifedipine; Pulmonary A | 1991 |
When lungs on mountains leak. Studying pulmonary edema at high altitudes.
Topics: Altitude Sickness; Humans; Mountaineering; Nifedipine; Pulmonary Edema | 1991 |
Effect of nifedipine on oxygen delivery in canine asymmetric oleic acid lung injury.
Topics: Animals; Dogs; Hemodynamics; Infusions, Intravenous; Nifedipine; Oxygen; Oxygen Consumption; Pulmona | 1990 |
Nifedipine for high altitude pulmonary oedema.
Topics: Acute Disease; Administration, Sublingual; Adult; Altitude Sickness; Delayed-Action Preparations; Ec | 1989 |
[A case of acute respiratory failure precipitated by long-acting nifedipine].
Topics: Acute Disease; Aged; Delayed-Action Preparations; Drug Hypersensitivity; Humans; Hypertension; Male; | 1988 |
A case of high-altitude pulmonary edema treated with nifedipine.
Topics: Altitude Sickness; Emergencies; Humans; Hypoxia; Male; Nifedipine; Pulmonary Edema | 1987 |
Pulmonary edema with nifedipine in primary pulmonary hypertension.
Topics: Adult; Female; Humans; Hypertension, Pulmonary; Nifedipine; Pulmonary Edema | 1985 |